Community Medicine
7 questionsWhat is the key characteristic of Body Mass Index (BMI) considerations for the Asian population?
What is the role of iodized salt in the iodine deficiency control programme?
Which of the following is not classified as a special incidence rate?
Which of the following is not typically screened for in blood donations?
What is the osmolarity of the new Oral Rehydration Solution (ORS)?
What is the significance of a 2-year post-treatment surveillance period in paucibacillary leprosy?
Berksonian bias is a type of ?
NEET-PG 2012 - Community Medicine NEET-PG Practice Questions and MCQs
Question 771: What is the key characteristic of Body Mass Index (BMI) considerations for the Asian population?
- A. Increased morbidity at lower values (Correct Answer)
- B. BMI cut-offs for obesity differ from international standards
- C. Increased morbidity at higher BMI values
- D. Obesity is defined as > 25 kg/m2
Explanation: ***Increased morbidity at lower values*** - Due to differences in body composition and fat distribution, Asian populations tend to experience **higher risks of developing obesity-related diseases** (e.g., type 2 diabetes, cardiovascular disease) at **lower BMI values** compared to non-Asian populations. - This increased morbidity at lower BMI values highlights the need for population-specific BMI cut-offs for health risk assessment. *BMI cut-offs for obesity differ from international standards* - While it is true that **BMI cut-offs for obesity differ for Asian populations**, this option does not fully describe *why* these cut-offs differ. - The difference in cut-offs is precisely *because* increased morbidity is seen at lower BMI values, making this option less specific than the correct answer. *Increased morbidity at higher BMI values* - While morbidity does increase at higher BMI values in all populations, this statement is **true for Caucasians and other populations**, but the defining characteristic for Asian populations is the *lower* BMI at which morbidity risk begins to significantly increase. - This option does not capture the unique aspect of BMI and health risks in the Asian population. *Obesity is defined as > 25 kg/m2* - For many Asian populations, a BMI of **> 25 kg/m²** is often used as the cut-off for **overweight**, not necessarily obesity, and **obesity is often defined at > 27.5 kg/m² or 30 kg/m² depending on the specific group**. - The international standard for obesity (BMI ≥ 30 kg/m²) is often considered too high for many Asian populations to capture risk effectively.
Question 772: What is the role of iodized salt in the iodine deficiency control programme?
- A. Primary prevention of iodine deficiency (Correct Answer)
- B. Secondary prevention of iodine deficiency
- C. Tertiary prevention of iodine deficiency
- D. Not applicable
Explanation: ***Primary prevention of iodine deficiency*** - **Iodized salt** is a population-wide strategy to ensure adequate **iodine intake** in communities, preventing deficiency before it even occurs. - It aims to maintain normal **thyroid hormone** production and prevent disorders like **goiter** and **cretinism** in healthy individuals. *Secondary prevention of iodine deficiency* - **Secondary prevention** focuses on early diagnosis and prompt treatment in individuals already showing signs of a disease to prevent progression. - While screening for **iodine deficiency disorders (IDD)** might be secondary prevention, the universal use of iodized salt is not targeted at already deficient individuals but at the entire population. *Tertiary prevention of iodine deficiency* - **Tertiary prevention** involves managing existing conditions to prevent complications, reduce disability, and improve quality of life after a disease has manifested. - This would involve treating conditions like **severe hypothyroidism** or **cretinism** that result from prolonged iodine deficiency, for which **iodized salt** is not a direct treatment but a preventative measure. *Not applicable* - This option is incorrect as **iodized salt** plays a crucial and well-established role in public health for controlling **iodine deficiency**. - The scientific evidence and public health initiatives globally highlight its significant applicability in preventing **iodine deficiency disorders**.
Question 773: Which of the following is not classified as a special incidence rate?
- A. Attack rate
- B. Secondary attack rate
- C. Hospital admission rate
- D. Standardized mortality rate (Correct Answer)
Explanation: ***Standardized mortality rate*** - This is a measure used to compare **mortality rates** between different populations, adjusting for age or other confounding factors. - It is a **standardized mortality measure**, not an incidence rate, and therefore not classified as a special incidence rate. - Special incidence rates measure the occurrence of **new cases** in specific circumstances, whereas SMR is a **comparative mortality metric**. *Attack rate* - The **attack rate** is a classic **special incidence rate** used to describe the proportion of people in a population who became ill during an **epidemic or outbreak**. - It is specifically calculated during a **short, well-defined period**, often relevant to foodborne illnesses or infectious disease outbreaks. *Secondary attack rate* - The **secondary attack rate** is a **special incidence rate** that measures the proportion of susceptible people who develop a disease after being exposed to a **primary case** within a defined population (e.g., household contacts). - It quantifies the **spread of an infectious agent** within a closed population after its introduction. *Hospital admission rate* - This is a **health service utilization indicator** that measures hospital admissions in a population during a specified period. - It is **not classified as a special incidence rate** in standard epidemiological teaching, as it reflects healthcare utilization rather than disease occurrence in outbreak situations.
Question 774: Which of the following is not typically screened for in blood donations?
- A. HIV
- B. HBV
- C. HCV
- D. Epstein-Barr Virus (EBV) (Correct Answer)
Explanation: ***Epstein-Barr Virus (EBV)*** ✓ - EBV is **NOT routinely screened** for in blood donations in India and most countries - While EBV is a common virus (>90% adults are seropositive), it is **not considered a major transfusion-transmitted infection** - The virus is primarily transmitted through saliva; transfusion-associated EBV transmission is **extremely rare and usually not clinically significant** in immunocompetent recipients - Risk-benefit analysis does not support routine screening due to **high prevalence, low clinical impact, and cost considerations** - EBV screening may only be considered for specific recipients (e.g., severely immunocompromised patients) *HIV* - **Routinely screened** in all blood donations worldwide - Screening includes HIV-1 and HIV-2 antibodies and/or HIV antigen/RNA testing - Transfusion-transmitted HIV causes AIDS with severe consequences - Mandatory screening under the Drugs and Cosmetics Act in India *HBV* - **Routinely screened** in all blood donations - Screening includes HBsAg (Hepatitis B surface antigen) testing, and often anti-HBc or HBV DNA - Can cause acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma - Mandatory screening in India and globally *HCV* - **Routinely screened** in all blood donations - Screening includes anti-HCV antibodies and/or HCV RNA (nucleic acid testing) - Major cause of chronic hepatitis, cirrhosis, and liver cancer - Mandatory screening under blood safety regulations
Question 775: What is the osmolarity of the new Oral Rehydration Solution (ORS)?
- A. 270
- B. 245 (Correct Answer)
- C. 290
- D. 310
Explanation: ***245*** - The **new ORS (reduced osmolarity ORS)** has an osmolarity of **245 mOsmol/L**. - This reduced osmolarity formulation has been shown to be more effective in reducing stool output, vomiting, and duration of diarrhea compared to the standard ORS. *270* - While 270 mOsmol/L is closer to the target, it is not the exact osmolarity of the **new ORS formulation**. - The precise osmolarity of the new ORS is specifically designed for optimal water and electrolyte absorption. *290* - The **standard (or traditional) ORS** had an osmolarity of **310 mOsmol/L**, which is higher than 290 mOsmol/L. - An osmolarity of 290 mOsmol/L does not correspond to a recognized standard or new ORS formulation. *310* - The **standard (or traditional) ORS** formulation had an osmolarity of **310 mOsmol/L**. - The move to a new ORS with reduced osmolarity was to improve efficacy and reduce the risk of hypernatremia in some patients.
Question 776: What is the significance of a 2-year post-treatment surveillance period in paucibacillary leprosy?
- A. To monitor for treatment compliance during active therapy
- B. To assess the effectiveness of multibacillary leprosy treatment protocols
- C. To detect early signs of drug resistance in ongoing treatment
- D. To identify relapses, reactions, and neurological complications after treatment completion (Correct Answer)
Explanation: ***To identify relapses, reactions, and neurological complications after treatment completion*** - The 2-year post-treatment surveillance period for **paucibacillary leprosy** is crucial for monitoring for **relapses** which can occur even after successful multidrug therapy (MDT). - It also allows for the early detection and management of **leprosy reactions** (e.g., Type 1 reversal reactions) and **neurological complications** such as nerve damage, which can develop or progress after treatment completion. *To monitor for treatment compliance during active therapy* - Monitoring for **treatment compliance** occurs *during* the active 6-month MDT period for paucibacillary leprosy, not primarily in the 2-year post-treatment surveillance phase. - While compliance is essential for successful treatment, the post-treatment period is focused on after-effects. *To assess the effectiveness of multibacillary leprosy treatment protocols* - This surveillance period is specifically for **paucibacillary leprosy**, which has a different treatment regimen and surveillance duration (6 months MDT followed by 2 years surveillance) compared to multibacillary leprosy (12 months MDT followed by 5 years surveillance). - The effectiveness of multibacillary treatment protocols would be assessed over a longer period following completion of its own specific MDT. *To detect early signs of drug resistance in ongoing treatment* - Detection of **drug resistance** is typically assessed *during* treatment if a patient is not responding clinically or shows signs of worsening, or in cases of relapse where drug resistance might be suspected as the cause. - While possible, the primary purpose of post-treatment surveillance is broader than just drug resistance; it encompasses all potential adverse long-term outcomes.
Question 777: Berksonian bias is a type of ?
- A. Selection bias (Correct Answer)
- B. Information bias
- C. Interviewer bias
- D. Recall bias
Explanation: ***Selection bias*** - **Berkson's bias** is a form of **selection bias** that arises in studies conducted using hospital data. - It occurs when the probability of admission to a hospital or inclusion in a study is conditional on both exposure and disease status, leading to a **flawed association** between them. *Interviewer bias* - **Interviewer bias** is a type of **information bias** where the interviewer's expectations or knowledge about the study or participants influence the way information is sought or recorded. - This typically affects the **data collection process** and not the selection of participants. *Information bias* - **Information bias** is a broad category of biases that arise from **systematic errors in measurement** or classification of exposure or disease. - While Berkson's bias can lead to misinformation, its root cause is in how subjects are selected, not how data on those subjects is collected after selection. *Recall bias* - **Recall bias** is a type of **information bias** where there are systematic differences in the way participants **recall past events or exposures**. - It is particularly common in **case-control studies** where individuals with a disease may remember exposures differently than healthy controls.
Internal Medicine
1 questionsWhat is the primary electrolyte found in Oral Rehydration Salts (ORS) at a concentration of 75 mEq/L?
NEET-PG 2012 - Internal Medicine NEET-PG Practice Questions and MCQs
Question 771: What is the primary electrolyte found in Oral Rehydration Salts (ORS) at a concentration of 75 mEq/L?
- A. Sodium (Correct Answer)
- B. Potassium
- C. Glucose
- D. Chloride
Explanation: ***Sodium*** - The primary electrolyte in **Oral Rehydration Salts (ORS)** is **sodium**, which is crucial for replacing losses due to diarrhea and facilitating water absorption in the intestines [1]. - The standard ORS formulation, recommended by the WHO, contains **75 mEq/L of sodium** to effectively rehydrate individuals with acute watery diarrhea [1]. *Potassium* - While **potassium** is an essential electrolyte found in ORS, its concentration is typically lower than sodium, usually around **20 mEq/L**. - Potassium helps replenish intracellular losses and supports normal cellular function, but it is not the primary electrolyte at the 75 mEq/L concentration. *Glucose* - **Glucose** is a crucial component of ORS, but it is a sugar, not an electrolyte. - Its role is to facilitate the co-transport of **sodium and water** across the intestinal wall, enhancing fluid absorption, but it does not contribute to the electrolyte concentration in mEq/L [1]. *Chloride* - **Chloride** is an electrolyte present in ORS, primarily to balance the charge of **sodium** and prevent hyynatremia. - Its concentration is typically around **65 mEq/L**, making it slightly less concentrated than sodium but still vital for maintaining electrolyte balance.
Obstetrics and Gynecology
1 questionsWhat is the energy requirement in late pregnancy?
NEET-PG 2012 - Obstetrics and Gynecology NEET-PG Practice Questions and MCQs
Question 771: What is the energy requirement in late pregnancy?
- A. 2000 calories
- B. 2500 calories (Correct Answer)
- C. 1400 calories
- D. 3000 calories
Explanation: ***2500 calories*** - The energy requirement for women in late pregnancy (third trimester) is approximately **2300-2500 calories per day**, which includes an additional **300-450 calories** above pre-pregnancy needs. - This increased energy intake supports **fetal growth and development**, increased maternal blood volume, uterine growth, and the metabolic demands of pregnancy. - The **2500 calorie** recommendation represents the upper range suitable for most pregnant women with normal activity levels. *2000 calories* - This amount is closer to the **pre-pregnancy energy requirement** for an average woman, but is **insufficient** for late pregnancy. - During the third trimester, failing to meet increased caloric needs can compromise **fetal growth** and lead to **inadequate gestational weight gain**. *1400 calories* - This amount is **severely insufficient** for the increased metabolic demands of late pregnancy. - An inadequate calorie intake can compromise **fetal growth**, lead to **intrauterine growth restriction (IUGR)**, and cause **maternal nutrient deficiencies**. *3000 calories* - This caloric intake is generally **too high** for the average pregnant woman with normal activity levels. - Excessive intake is only justified in cases of **multiple gestation**, unusually high physical activity, or specific medical conditions. - Consuming 3000 calories per day without proper justification can lead to **excessive gestational weight gain**, gestational diabetes, and macrosomia.
Pharmacology
1 questionsWhat is the primary reason for using a combination of four drugs in Anti-Koch's Treatment (AKT) for tuberculosis?
NEET-PG 2012 - Pharmacology NEET-PG Practice Questions and MCQs
Question 771: What is the primary reason for using a combination of four drugs in Anti-Koch's Treatment (AKT) for tuberculosis?
- A. To decrease the risk of resistance due to mutation. (Correct Answer)
- B. To decrease the risk of resistance due to conjugation.
- C. To enhance overall treatment efficacy.
- D. To simplify treatment.
Explanation: ***To decrease the risk of resistance due to mutation*** - **Tuberculosis bacteria** can spontaneously develop resistance to a single drug through **random genetic mutations**. - Using multiple drugs simultaneously significantly reduces the probability that a bacterium will spontaneously develop resistance to **all drugs** in the regimen. - This is the **primary rationale** for multi-drug therapy in TB, as emphasized by WHO guidelines. *To decrease the risk of resistance due to conjugation* - **Conjugation** is a mechanism of horizontal gene transfer in bacteria, primarily involving the transfer of plasmids. - While important for antibiotic resistance in some bacteria, it is **not the primary mechanism** of resistance development in *Mycobacterium tuberculosis*. - TB resistance develops mainly through **chromosomal mutations**, not plasmid transfer. *To enhance overall treatment efficacy* - While multi-drug regimens do enhance treatment efficacy by targeting different bacterial populations (actively dividing, slow-growing, dormant), this is a **consequence** of the multi-drug approach. - The **primary reason** for using four drugs specifically is to prevent the emergence of **drug-resistant mutants**. - Enhanced efficacy is achieved *because* resistance is prevented, making this a secondary benefit. *To simplify treatment* - A four-drug regimen actually makes treatment more **complex** due to multiple pills, potential drug interactions, and increased side effects. - The complexity is a necessary trade-off for **resistance prevention** and treatment success.